Introduction to a review series on follicular lymphoma: solved or insoluble problem?

Abstract

Although there have been many therapeutic advances in follicular lymphoma (FL) in recent years, important questions remain about how best to integrate emerging biologic insights with evolving treatment options. To address these challenges, Associate Editor Philippe Armand has assembled a comprehensive review series. Araujo-Ayala and Béguelin highlight recent advances in the biological understanding of FL, including its evolutionary pathways and therapeutic vulnerabilities. Bachy and Linton examine the challenges of designing and conducting frontline clinical trials and propose strategies to overcome them. Casulo and Sehn outline a personalized approach to managing relapsed or refractory FL. Mulvey et al explore the promise of novel assays and treatments that may shape the next era of FL care. Di et al consider key issues in trial design, particularly given the prolonged benefit seen with many current therapies. Parry and Okosun review the biology of histologic transformation and its clinical management, which is still one of the most difficult aspects of FL treatment.